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Abstract
Background. Oligodendroglioma is a rare primary central nervous system (CNS) tumor with highly variable out-
come and for which therapy is usually not curative. At present, little is known regarding the pathways involved with 
progression of oligodendrogliomas or optimal biomarkers for stratifying risk. Developing new therapies for this 
rare cancer is especially challenging. To overcome these challenges, the neuro-oncology community must be par-
ticularly innovative, seeking multi-institutional and international collaborations, and establishing partnerships with 
patients and advocacy groups thereby ensuring that each patient enrolled in a study is as informative as possible.
Methods. The mission of the National Cancer Institute’s NCI-CONNECT program is to address the challenges and 
unmet needs in rare CNS cancer research and treatment by connecting patients, health care providers, researchers, 
and advocacy organizations to work in partnership. On November 19, 2018, the program convened a workshop on 
oligodendroglioma, one of the 12 rare CNS cancers included in its initial portfolio. The purpose of this workshop 
was to discuss scientific progress and regulatory challenges in oligodendroglioma research and develop a call to 
action to advance research and treatment for this cancer.
Results. The recommendations of the workshop include a multifaceted and interrelated approach covering: bi-
ology and preclinical models, data sharing and advanced molecular diagnosis and imaging; clinical trial design; 
and patient outreach and engagement.
Conclusions. The NCI-CONNECT program is well positioned to address challenges in oligodendroglioma care and 
research in collaboration with other stakeholders and is developing a list of action items for future initiatives.
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Key Points
1  Patients with oligodendroglioma have highly variable outcome and therapy is 
usually not curative.
2  Risk stratification biomarkers and pathways involved with resistance to therapy 
and progression are being investigated.
3  The NCI-CONNECT Workshop provides a call to action to address challenges in 
patient care and research.
Introduction and Background
Developing therapies for rare cancers of the central nervous 
system (CNS) is especially formidable for several reasons. 
First, unlike some other diseases, including many cancers, 
there are few good preclinical models on which to build clin-
ical trials. Second, the complexity of the CNS and potential 
for therapy-induced injury poses strategic, pragmatic, and 
ethical challenges. Third, there are inherent challenges in 
both providing care and conducting clinical research. These 
challenges include the potential for delays in diagnosis, 
lack of well-defined standards of care, limited social and ad-
vocacy support, and difficulties in conducting clinical trials 
because of low incidence compounded by the limited ex-
perience of health care providers, even those in academic 
centers with specialized neuro-oncology programs. As these 
cancers are extremely rare, it is difficult to recruit enough pa-
tients to statistically power a study. To overcome these mul-
tilayered challenges, the neuro-oncology community must 
be particularly innovative, seeking multi-institutional and in-
ternational collaboration, and establishing partnerships with 
patients and advocacy groups thereby ensuring that each pa-
tient enrolled in a study is as informative as possible.
Responding to the Challenges
The Beau Biden Cancer Moonshot Program, part of the 21st 
Century Cures Act, appropriated $1.7 billion toward cancer 
care in 10 select areas, including patient engagement. The 
National Cancer Institute (NCI) was granted support from 
this program to focus specifically on adult rare CNS tumors 
through the NCI-CONNECT program, housed in the Neuro-
Oncology Branch in NCI’s Center for Cancer Research. The 
program’s mission is to address the challenges and unmet 
needs in adult rare CNS cancer research and treatment by 
connecting patients, health care providers, researchers, 
and advocacy organizations to work in partnership. The 
program is first focusing on 12 types of rare CNS tumors, 
each with less than 2,000 people diagnosed a year in the 
United States. NCI-CONNECT has three program goals: (1) 
develop an infrastructure across a network of national and 
international sites to study select adult rare CNS tumors; 
(2) collect, analyze, and share information to promote dis-
covery and improve understanding of adult rare CNS tu-
mors; and (3) build the network to facilitate the translation 
of discoveries into new therapies through collaborative ef-
forts to improve patient clinical outcomes.
As part of NCI-CONNECT, the Neuro-Oncology Branch 
has undertaken a large international study, the “Outcomes 
and Risk Study for Patients with Rare Brain and Spine 
Tumors,” which aims to refine the molecular classifica-
tion of these rare cancers so that physicians will be able 
to give a more accurate prognosis to patients as well as 
select more appropriate treatments that have a greater 
likelihood of being effective in any individual tumor. It also 
aims to uncover risk factors that might increase a person’s 
chances of developing brain or spine cancer. Another 
study, “Evaluation of the Natural History and Specimen 
Banking for Patients with CNS Cancers,” was developed 
to better understand brain and spinal cord tumors to un-
cover areas for future research. NCI-CONNECT also sup-
ports several treatment trials, including investigation of 
the immunotherapy drug nivolumab for treating rare CNS 
tumors, the multitargeted kinase inhibitor sunitinib for re-
current gliosarcomas and primary CNS sarcomas, the pro-
teasome inhibitor marizomib for recurrent ependymoma, 
and the antiangiogenic agent bevacizumab in combination 
with carboplatin for recurrent ependymoma.
Partnering with advocacy groups and patients is critical 
to NCI-CONNECT’s mission; to advance the understanding 
of rare adult CNS cancers by establishing and fostering 
patient–advocacy–provider partnerships and networks 
to improve approaches to care and treatment. This could 
lead to increased patient accrual to the program, care, 
and studies, which take place at the National Institutes of 
Health (NIH) Clinical Center or one of the more than 30 in-
stitutions in the Brain Tumor Trials Collaborative (BTTC) 
network. An important contribution of NCI-CONNECT is 
its convening power, that is, the ability to bring experts 
in rare CNS cancers together to share insights, ideas, 
and plans for collaboration. On November 19, 2018, NCI-
CONNECT convened a workshop on oligodendroglioma, 
one of the 12 rare CNS cancers included in its initial port-
folio. (See https://ccr.cancer.gov/neuro-oncology-branch/
connect for the complete list.) This manuscript sum-
marizes the proceedings of this workshop. Worldwide 
neuro-oncology experts from different disciplines and ad-
vocacy partners met to discuss the molecular pathology of 
oligodendrogliomas, preclinical models, clinical trial effi-
cacy endpoints, and collaborative efforts in data sharing. 
Presentations by leaders in the field on important areas 
of scientific progress and associated challenges were fol-
lowed by in-depth discussions by all participants divided 
in working groups. Participants recognized the need to 
combine data, resources, and samples to develop better 











treatments for patients with oligodendrogliomas. An ac-
tion plan to address challenges in patient care and re-
search was developed.
About Oligodendroglioma
Oligodendroglioma is a primary CNS tumor believed 
to originate from oligodendroglial precursor cells. 
Oligodendrogliomas are diffusely infiltrative gliomas mo-
lecularly defined by isocitrate dehydrogenase (IDH) mu-
tation and codeletion of the short arm of chromosome 1 
(1p) and the long arm of chromosome 19 (19q), according 
to the World Health Organization (WHO) 2016 classifi-
cation.1 Additionally, they are historically classified into 
two grades, WHO grade II or low grade and grade III or 
anaplastic, based on their histological characteristics. 
Other common molecular alterations are described later 
in this manuscript.2,3 Oligodendrogliomas represent less 
than 10% of all gliomas.4 Whereas oligodendroglial tumors 
share common molecular features and typically have a 
better prognosis than astrocytic tumors, they still have 
highly variable clinical outcomes even within the same 
WHO grade (Figures 1 and 2). At present, little is known re-
garding the pathways involved with resistance to therapy 
and progression of oligodendrogliomas or optimal bio-
markers for stratifying risk.
Oligodendrogliomas occur most often in young adults 
between the ages of 35 and 44 but can occur at any age. 
They occur slightly more often in males and are rare in 
children, in whom despite presenting classical histolog-
ical features, the molecular characteristics differ from 
adults (typically IDH/TERTp/1p19q wild type), with clinical 
implications that are not fully understood.5,6 According to 
the Central Brain Tumor Registry of the United States, an 
estimated 11,757 people are living with this tumor in the 
United States. The 5-year survival rate is 74.1%.4
Symptoms of oligodendroglioma depend on the size 
and location of the tumor. The most common presenting 
symptom is a seizure, which approximately 60% of patients 
experience before being diagnosed.7 Other commonly 
occurring symptoms include headaches, memory loss and 
other cognitive difficulties, focal weakness and/or sensory 
deficits, or problems with balance and movement. The first 
intervention is surgery, which allows to make a tissue-based 
diagnosis including molecular marker assessment; further, 
surgery is a therapeutic measure and aims to remove as 
much tumor as possible without causing more neurological 
deficits. Current treatment guidelines are based on phase 
3 clinical trials which were designed separately for grade II 
and grade III tumors and before the establishment of molec-
ular criteria for the diagnosis of oligodendroglioma. Upfront 
treatment options for low-grade oligodendrogliomas in-
clude observation alone (typically for patients under the 
  
Figure 1. Axial T2/FLAIR MRI images of patient with left 
occipitoparietal oligodendroglioma WHO grade 2, IDH1 mutated, 
1p19q codeleted with indolent course. (A) Incidental finding at age 
39, followed with serial imaging without intervention. (B) Near total 
resection at age 41 after slight increase in T2/FLAIR hyperintensity 
and development of headaches, then followed without additional 
treatment. (C) Slight increase in T2/FLAIR hyperintensity adjacent 
to the surgical cavity at age 52 (13 years from initial imaging diag-






Figure 2. Axial T1 with contrast and T2/FLAIR MRI images of pa-
tient with left posterior temporal oligodendroglioma WHO grade 2, 
IDH1 mutated, 1p19q codeleted with aggressive course. (A) Imaging 
at age 28 after presenting with seizures; underwent biopsy without 
further treatment. (B) Imaging at age 31 after biopsy demonstrating 
transformation to anaplastic oligodendroglioma. Patient had re-
ceived 2  years of therapy with temozolomide due to imaging pro-
gression detected 6  months after initial diagnosis. (C) Imaging 
preresection (right) and postresection (left) at the time of 4th pro-
gression (age 37), after having received radiation, procarbazine and 
lomustine; received subsequent treatment with re-irradiation and 
with a PD-1 inhibitor 3 years later for new recurrence.
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age of 40 with gross total resection of tumor) and radiation 
with adjuvant chemotherapy for patients not meeting these 
criteria (procarbazine/CCNU/vincristine or PCV, category 
1; temozolomide, category 2B according to NCCN guide-
lines8). Anaplastic oligodendrogliomas are typically treated 
with radiation and adjuvant PCV chemotherapy (category 1 
according to NCCN guidelines8) or adjuvant temozolomide 
with or without concurrent temozolomide.8–12 An ongoing 
international phase 3 clinical trial (CODEL, NCT00887146) 
is comparing the efficacy of radiotherapy with concomitant 
temozolomide followed by adjuvant temozolomide, versus 
radiotherapy with adjuvant PCV in patients with newly 
diagnosed anaplastic gliomas and high-risk low-grade 
gliomas with 1p/19q codeletion. Whether radiotherapy can 
be deferred to prevent radiotherapy-induced neurotoxicity 
in anaplastic oligodendrogliomas is currently being inves-
tigated in the POLCA trial, comparing upfront radiotherapy 
plus PCV versus upfront PCV plus deferred radiotherapy 
at progression (NCT02444000). Many questions remain 
regarding treatment of oligodendrogliomas, including 
the optimal time for initiation of therapy in low-grade tu-
mors, the relative efficacy of PCV versus temozolomide, the 
identification of favorable molecular markers beyond IDH 
mutation13 and 1p19q codeletion14 (which are now disease-
defining and no longer prognostic within the histology), the 
potential role of de-escalation of therapy for patients with 
such favorable molecular markers, and the optimal therapy 
for recurrent tumors.
Scientific Progress and Regulatory 
Challenges in Oligodendroglioma 
Research
To frame the discussion of the working groups, three im-
portant and separate areas of scientific progress and chal-
lenges were reviewed, as summarized below.
The Molecular Characteristics of 
Oligodendroglioma: Implications for 
Diagnosis and Prognosis
Presented by Daniel J.  Brat, M.D., Ph.D., Northwestern 
University Feinberg School of Medicine.
Oligodendrogliomas were first defined histopatho-
logically in the 1920s. The oligodendrocyte had only 
been defined as a type of glial cell in the 10 years prior. 
Although treatment strategies have not evolved signif-
icantly over recent years, the ability to stratify risk has 
improved, based increasingly on molecular alterations. 
Although oligodendrogliomas are defined by the pres-
ence of IDH mutations and 1p/19q codeletion, they also 
frequently harbor mutations in the TERT promoter, CIC, 
FUBP1,3 and NOTCH1. In addition, these tumors are more 
chemosensitive than their IDH1/2 mutated astrocytic coun-
terparts, possibly due to the 1p/19q codeletion that accom-
panies the IDH mutations.15,16
Review of gliomas based on their mutational 
status shows that oligodendrogliomas have a 
specific profile, and there is little molecular overlap 
among oligodendrogliomas, IDH mutant astrocytomas, 
and IDH wild-type high-grade gliomas. Genes mutated 
in oligodendrogliomas such as CIC, NOTCH1, FUBP1, are 
typically not mutated in astrocytomas. These specific mo-
lecular fingerprints of glioma subtypes led the WHO in 
2016 to distinguish between oligodendrogliomas and 
astrocytomas based on their molecular characterization. 
This also resulted in the recognition that the tumor pre-
viously called oligoastrocytoma did not have a molecular 
signature and should not be used as a diagnosis when 
molecular testing is available.1 This new paradigm has 
led to an ability to establish reproducible and clinically 
meaningful diagnoses that stratify risk based on molec-
ular classes rather than on histological findings such as cell 
morphology, nuclear atypia and vascular proliferation, or 
necrosis. Leveraging this molecular characterization can 
point to biomarkers and mechanisms that drive tumor pro-
gression so that therapies can be directed against them.
Within each molecular class of diffuse glioma, there is cur-
rently a desire to use molecular markers to further stratify 
risk17 and serve as tools for grading. One study in Japan in-
vestigated two cohorts of patients with oligodendroglioma 
whose tumors had been genetically sequenced.18 Based on 
multivariate analysis, it was determined that incomplete 
neurosurgical resection and the presence of NOTCH1 muta-
tions—which are found specifically in oligodendrogliomas 
but not in IDH mutant astrocytomas or molecularly defined 
glioblastomas—were two independent predictors of poor 
overall survival. Patients who had an extensive resection 
and did not have NOTCH1 mutations had good clinical out-
comes long-term. Based on these findings, Brat et al. are 
developing clinical decision support algorithms to predict 
patient outcomes and guide treatment decisions. Like the 
Japanese cohort, Brat et  al.’s analyses demonstrated that 
NOTCH1 pathway inactivation and PI3K pathway activa-
tion are strongly associated with poor clinical outcome.19 
Further analyses showed that every member of the NOTCH 
pathway is upregulated dramatically in patients with pro-
longed survival, suggesting a pathway effect.
In addition to reviewing overall survival and progression-
free survival, Brat et al. analyzed endpoints associated with 
disease progression, such as contrast enhancement on 
magnetic resonance imaging (MRI), high-cellular density 
in digitized histopathologic images, and increased cellular 
proliferation. They searched for enrichment of specific mu-
tations in those tumors with radiologic or pathologic fea-
ture of a higher grade. The contrast-enhancing tumors were 
found to have NOTCH1 mutations, as well as shorter overall 
survival. Similar correlations were found with regard to cell 
density and proliferation. In comparison, the nonenhancing 
tumors are genetically relatively silent. Although NOTCH1 
mutations are important in the progression of this disease, 
but other prognostic markers include PI3K pathway activa-
tion and loss of chromosomes 14q and 15q.
Evolution and Progression of Low-Grade Glioma
Presented by Joseph F.  Costello, Ph.D., University of 
California, San Francisco.











Costello et al. have focused on how oligodendrogliomas 
initiate and progress through malignant transformation 
(ie, change to a higher histological grade and development 
of resistance to therapy). Their goal is to understand the 
mechanism of malignant transformation to ultimately de-
velop strategies to reduce its occurrence.
Using multiple samples from each tumor and accounting 
for diversity in the genetic makeup in different parts of 
the tumor, basic techniques of genetic phylogenies can 
be traced back in time.20 In some cases, the first mutation 
that occurred earlier in an individual patient’s tumor can 
be determined. A  phylogenetic tree can be constructed 
that tracks the evolution in the mutations. In the example 
provided in Figure 3 (tumor evolution in a primary 1p19q 
codeleted, IDH2 mutant low-grade oligodendroglioma), 
one can infer that in some cases the recurrence can differ 
from the primary tumor (shares some mutations but has 
a greater number of nonshared mutations). Piecing this 
and other information together, a hypothesis of the steps 
in the formation of a low-grade glioma can be constructed, 
including improved understanding of epigenetic and met-
abolic effects, immune reprogramming, and immunosup-
pression, all induced by the IDH mutation. The cell cycle 
is dysregulated through the TP53 mutation and results in 
reduction in the ability of the cell to undergo apoptosis, 
making it more resistant to therapy. Regulation of the cell 
telomeres, and therefore mortality, is influenced by the 
ATRX mutation in astrocytoma and the TERT promoter 
mutation in oligodendroglioma.
Costello et  al. have developed a model of low-grade 
glioma initiation and malignant transformation with dis-
ease recurrence. There is great interest in the genetic char-
acterization of cells that are left behind following surgical 
resection as they can provide clues to the vulnerabilities 
or resistance of the residual disease to which subsequent 
treatment is directed. With malignant transformation, 
tumors can recur as higher grade through spontaneous 
genetic events or through chemotherapy-associated 
increases in mutational burden including a profound 
increase in mutations often referred to as hypermuta-
tion.21 Preclinical studies findings suggested that the 
alkylating chemotherapy agent temozolomide might spur 
a series of reactions that may lead to resistance to the 
antitumor effect, consistent with findings from the ge-
nomic analysis of patient samples. However, this hypoth-
esis still needs further clinical confirmation and enters in 
conflict with the known clinical benefit of temozolomide 
in oligodendroglial tumors. Thus, according to these pre-
liminary findings, this agent could evolve from being cy-
totoxic to the tumor cells and beneficial to creating more 
mutations that confer resistance at the time of relapse. 
Costello et al. have shown that the signature of this che-
motherapy can be seen in the exome sequencing of re-
current tumors.22 Hypermutation after temozolomide is 
statistically associated with an increase in malignancy 
grade in these studies; that is, the mutations created by 
chemotherapy are contributing or driving the process 
of malignant transformation. Further studies have 
shown that although hypermutation most commonly 
occurs in astrocytoma it can also be detected readily in 
oligodendrogliomas. The mutations created by the drug 
are promoting faster growth, because a critical check-
point on cell growth is eliminated by mutations occurring 
following chemotherapy, such as RB and AKT-mTOR 
pathway mutations. However, the clinical significance 
of these findings is still unclear. To date, the impact of a 
hypermutator versus a nonhypermutator oligodendro-
glioma on patient’s overall survival has not been evaluated 
prospectively, and clinical trials have shown improved 
overall survival if chemotherapy is added early on to radi-
otherapy in oligodendrogliomas, raising the question of to 
what extent these observations impact clinical outcome.
The Glioma Longitudinal AnalySiS (GLASS) Consortium 
(https://www.glass-consortium.org/) has shown an 
increase in the number of CIC mutations after recur-
rence, suggesting that CIC is a marker of secondary pro-
gression. Further, almost all recurrent hypermutated 
oligodendrogliomas appear to have a defect in the P53 
pathway. In fact, analysis of the enrichment of pathway 
mutations in hypermutated oligodendrogliomas reveals 
that TP53 is the most enriched gene in these tumors and 
likely a player in hypermutated oligodendroglioma. This 
suggests that perhaps the cells that are hypermutated re-
spond differently to therapy because TP53 has such a pro-
found effect on their response.
Additional retrospective data on a small number of 
cases suggest that the genotype of hypermutation is clini-
cally relevant, although this requires further confirmation 
in larger and prospective datasets. At recurrence, pa-
tients with a hypermutated tumor have a shorter overall 
survival, suggesting that the hypermutator clone is more 
aggressive than the standard grade III glioma when data 
are adjusted for both age and subtype. The time between 
the point of first chemotherapy and recurrence with a 
hypermutator varies widely. Understanding the issues 
of latency and tumor dormancy is the next challenge. 









Figure 3. Early origin of recurrence from a grade II oligodendro-
glioma. Tumor evolution inferred from mutations in a primary 1p19q 
codeleted, IDH2 mutant low-grade oligodendroglioma and two 
tumor samples from a subsequent tumor recurrence from the same 
patient, resected years later (recurrence Y, recurrence G). The 
phylogenetic tree is derived from somatic mutations from exome 
sequencing of the tumor DNA samples. The length of each line in 
the phylogenetic tree is proportional to the number of mutations. 
The branch positions illustrate inferred points of evolutionary di-
vergence among the samples. The IDH2 mutation is shared by all 
three samples whereas a different CIC mutation is found in the ini-
tial sample versus in the two tumor samples at recurrence.
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needed to understand the actual rate of hypermutation in 
the treated population; preliminary data suggest the rate 
is about 20%, but the number of cases analyzed to date is 
small.
General Overview of Clinical Trial Efficacy 
Endpoints
Presented by Paul G.  Kluetz, M.D., U.S. Food and Drug 
Administration.
The Federal Food, Drug, and Cosmetic Act (FD&C Act) 
provides the framework for approval of new drugs based 
on substantial evidence of efficacy and acceptable safety 
for an indicated population. The Public Health Services Act 
requires evidence that biologic products be safe, pure, and 
potent for approval. The FDA Modernization Act clarified 
that the review and approval of drugs and biologics use 
a similar evidentiary framework, allowing for consistency 
in trial design and endpoint selection for registration trials 
to support cancer therapeutics. The traditional approval 
pathway relies on clinical benefit endpoints or established 
surrogate endpoints, in other words evidence of a “pro-
longation of life, a better life or an established surrogate.” 
Accelerated approval is based on endpoints other than ir-
reversible morbidity or mortality, and can rely on a surro-
gate endpoint reasonably likely to predict clinical benefit.23 
Because there is often residual uncertainty regarding clin-
ical benefit when using surrogate endpoints in the acceler-
ated approval program, post-marketing trials are needed to 
verify benefit. Direct measures of clinical benefit tend to be 
clinical outcomes, such as feeling or functioning better, or 
improvement in survival. In contrast, surrogate endpoints 
are not directly measuring symptoms, function, or sur-
vival, but rather look to predict benefit. In oncology this 
is most commonly based on control of tumor cell burden, 
which can be directly measured either through the blood 
in hematologic malignancy or through imaging of solid tu-
mors. Because tumor measures are monitored and acted 
upon in clinical practice (eg, changing therapies upon pro-
gression), response rate and progression-free survival are 
considered strong endpoints suitable for either regular or 
accelerated approval depending on the context and magni-
tude of effect.24
Clinical outcome assessments are used to quantify 
symptoms or function. These data can come from several 
sources, including clinician-reported outcomes, observer-
reported outcomes (someone other than the patient or 
health care provider), patient-reported outcomes, or 
performance-based outcomes.25 Wearable mobile tech-
nology tools may also provide an opportunity to gather 
data related to activity and other components of function.
When evaluating the strength and limitations of various 
types of efficacy endpoints, Dr. Kluetz stated that FDA will 
consider what is being measured (ie, endpoint selection) 
and whether it directly measures a clinical benefit (eg, sur-
vival, symptoms, or function) or whether it is a surrogate 
endpoint. Another consideration is the accuracy of the 
measure, its susceptibility to bias, subjectivity, or interpre-
tation, and the accuracy of the timing of the event. For an 
individual trial, the magnitude of effect on the endpoint is 
an important consideration. For example, in a single-arm 
trial of a chemotherapeutic agent treating patients with 
oligodendroglioma, a high rate of rapid, deep, and durable 
shrinkage of tumors across a cohort of patients would be 
compelling evidence of antitumor effect due to the inves-
tigational agent, given malignant tumors do not typically 
regress to a great extent on their own. Thus, treatment ef-
fect measured by tumor response can be a surrogate end-
point to support accelerated approval in the appropriate 
setting (specific disease, large magnitude of the effect, du-
rability of response).
Clinical benefit is determined based on the totality of 
data within a given context. A  critical component of the 
totality of data is the safety profile of the product. Acute 
and subacute safety and tolerability must be carefully 
characterized, including clinician-reported adverse events, 
dose modifications and, increasingly, patient-reported 
symptomatic toxicities and their impact on function. The 
agency will also consider other well-defined functional do-
mains that affect one’s health-related quality of life, such 
as cognition.
Moving the Field of Oligodendroglioma 
Research Forward – Reports from 
Working Groups
Workshop participants broke into four working groups to 
discuss issues related to advancing the field through col-
laborative research efforts to establish better preclinical 
models; data sharing and clinical research approaches, 
such as advanced imaging; optimization of clinical trial de-
signs; and promoting patient engagement.
Biology of Oligodendrogliomas and 
Preclinical Models
Session Leads: Daniel P.  Cahill, M.D., Ph.D., Harvard 
Medical School and J. Gregory Cairncross, M.D., University 
of Calgary.
Molecular diagnosis based on current WHO 2016 
criteria allows a more reliable classification of 
oligodendrogliomas and reflects tumor biology more ac-
curately. This provides an opportunity for further research. 
First, preclinical models are needed that emulate indolent 
disease. It is difficult to propagate cell lines either in vitro 
or these tumors in vivo. The limitations of animal models 
include the long time to achieve tumor growth and the 
relatively short lifespan of the animal, whereas some ca-
nine models that develop gliomas spontaneously are 
promising.26 Induced pluripotent stem (iPS) cells provide 
an opportunity to introduce the various mutations of the 
disease to generate a faithful model that can be used for 
in vitro studies. Recent success with creation of IDH mu-
tant mouse models for astrocytoma could be adapted to 
contain more oligodendroglioma-relevant genes.27–31
A second opportunity involves using clinical trial ma-
terials to develop correlative studies to understand the 
biology of oligodendroglioma, in particular, to collect 
image-guided tumor samples during longitudinal studies 
that might provide clues about early progression and 











spatial heterogeneity. For example, do patients who fail 
early have particular genetic alterations that could provide 
a window into what predicts poor prognosis?19,32,33
A third opportunity lies in identifying druggable targets 
for oligodendrogliomas. This could lead to preventive-type 
strategies, for example, screening patients for high-risk 
germline alterations34 and exposing people to a compa-
rably safe drug early in adulthood to decrease their lifetime 
risk of developing glioma.
These opportunities could be better pursued through 
access to a central repository containing human and 
animal tumor samples, prospective genomic analysis 
conducted in parallel with large clinical trials, and pro-
spective and continuous biospecimen monitoring to 
search for biomarkers for patients in the indolent phase 
of the disease.
Collaborative Efforts in Data Sharing and 
Incorporating Advanced Molecular Diagnosis 
and Advanced Imaging in Low Grade Glioma 
(LGG) Research
Session Leads: Terri S. Armstrong, Ph.D., 
NCI-CONNECT; Mark R. Gilbert, M.D., NCI-
CONNECT; Roel G.W. Verhaak, Ph.D., Jackson 
Laboratory for Genomic Medicine
Successful research networks require strong and well-
defined leadership, centralized infrastructure, clearly de-
fined policies (eg, data sharing, authorship), and funding. 
For example, the Cancer Genome Atlas has been suc-
cessful because of its infrastructure and large community 
of scientists. The GLASS consortium35,44 is emerging as an-
other robust effort in data aggregation and sharing. In each 
of these cases, champions for this effort and a commitment 
to inclusion and mutual value have brought success. NCI-
CONNECT is well positioned to partner and collaborate 
with such endeavors.
Future research efforts should consider the use of ex-
isting sources of data (alone or expanded) such as The 
Surveillance, Epidemiology, and End Results Program 
SEER https://seer.cancer.gov/ (some sites have sam-
ples) or case/control (eg, GICC,36 GLIOGENE37). Large co-
horts, such as the Nurses’ Health Study (https://www.
nurseshealthstudy.org/about-nhs), have stored vast 
amounts of clinical trial data that can be tapped for com-
parative controls. The AACR Project Genomics Evidence 
Neoplasia Information Exchange (GENIE; https://www.
aacr.org/Research/Research/pages/aacr-project-genie.
aspx) provides a model platform for oligodendrogliomas.
As new data collection goes forward, patient-level in-
formation is needed and long-term follow-up with clinical 
annotation is key. Although studies should always strive 
to answer specific questions, data collection need not be 
hypotheses-driven. For example, large companies collect 
vast amounts of data that can later be evaluated for trends 
or mined for profit. This is a model that should be emulated 
in science. Ideally, molecular and imaging data should be 
included in future data collection, noting that such efforts 
require additional time and resources.
Collaboration will be essential to acquire large longitu-
dinal sample collections, since historically sample sizes 
have typically been small and it is difficult to achieve sta-
tistical power. Additional efforts are needed to explore the 
value of serum- and CSF-derived biomarkers. In all cases, 
annotated tissue sampling will be critical to answering 
many questions.
A large amount of imaging data already exists and ef-
forts are needed to combine these data. Although pre 
and postoperative images tend to only include standard 
sequences that are essential, consideration should be 
given to adding advanced imaging studies such as perfu-
sion/diffusion, PET (18F-FDG, 11C-MET, others), and 2-HG 
spectroscopy when available, although many challenges 
remain regarding their implementation, value, indica-
tions and standardization among centers. Workshop par-
ticipants encouraged the use of the Brain Tumor Imaging 
Protocol (BTIP) for standardization.38 Existing imaging in-
frastructure (ie, Quantitative Image Informatics for Cancer 
Research [QIICR]) can be leveraged. Experience from the 
French POLA effort to study rare tumors has shown that 
the biggest challenge has been aggregating MRI images, 
as some institutions do not save images and there are dif-
ferences among institutions regarding what is saved and 
what patient privacy protections are needed. Finally, in 
cases where no tumor tissue is available, it may be pos-
sible to infer classification/genomic properties from radi-
ologic images, which may enable retrospective sample 
classification, although this remains speculative.
Clinical Trial Designs
Session Leads: Martin van den Bent, M.D., Ph.D., Erasmus 
MC Cancer Institute, and Marta Penas-Prado, M.D., 
NCI-CONNECT.
Given the typical long survival of patients with oligo-
dendroglioma, alternative clinical trial endpoints to 
progression-free survival and overall survival are needed 
that determine outcome and lead to more efficient trial 
designs. Examples include imaging endpoints evaluating 
growth trajectory, and clinical endpoints such as seizure 
control, objective testing of cognitive function, instrumental 
activities of daily living (ADLs), and symptom burden.39–43 
At present, imaging endpoints evaluating growth trajectory 
are an active subject of research by different groups but re-
main poorly defined and further studies are needed to val-
idate them, particularly as related to posttreatment growth 
rate changes. Use of composite endpoints, including evalu-
ation of imaging trajectory in combination with one or more 
clinical endpoints, should be considered for the design of 
future clinical trials. Randomization as opposed to the use 
of historical controls is also desirable for clinical trials that 
will be of long duration, as the historical control compar-
ison may be unreliable. Other trial designs to consider in-
clude Phase 0/proof-of-concept trials with tissue acquisition 
and pharmacodynamic endpoints after administration of 
experimental therapy to compensate for the lack of optimal 
preclinical models. However, these trials are challenging to 
implement and coordinate and are typically only feasible in 
a small number of experienced centers.
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Inclusion and exclusion criteria for trials can be better 
informed through molecular characterization as opposed 
to classical clinical factors (extent of resection, age), for 
example, to select patients who should not delay upfront 
therapy (those at greatest risk of progression due to a high-
risk molecular signature). Importantly, the working group 
emphasized the need for contemporary tissue sampling in 
trials for recurrent oligodendroglioma to assess molecular 
changes over time.
The group also recommended that tumor tissue and 
blood collection be made mandatory for future trials. 
Having tissue collected upfront would facilitate fu-
ture analyses as more information becomes available, 
rather than trying to obtain tumor tissue retrospectively 
to analyze recently discovered biomarkers once a pro-
spective study is completed. Given the low incidence of 
oligodendrogliomas, there should be initiatives launched 
to combine efforts that are not only multi-institutional but 
also international, recognizing regulatory, and logistical 
challenges. One potential alternative to conducting collab-
orative international trials creating an oligodendroglioma 
consortium similar to the AGILE consortium for glioblas-
toma (www.gcaresearch.org/gbm-agile/), which has led 
to the development of an international adaptive platform 
trial with an external contract research organization (CRO) 
in charge of supporting the trial (NCT03970447). However, 
for international studies, it is easier to pool data than to 
exchange tumor tissue samples or collaborate on trials 
given the increasingly complex regulatory environment 
for material transfer agreements and trial sponsorship. 
Existing longitudinal studies of cancer cohorts have relied 
on patients prospectively opting into data and specimen 
collection, which can eliminate some of the regulatory obs-
tacles to seeking permission retrospectively or obtaining 
institutional permission to do so. Despite these challenges, 















Biology and Preclinical Models
•  Develop appropriate models that recapitulate indolent disease
•   Analyze tissue longitudinally and identify and validate molecular markers of poor outcome in patients 
with early failure for introduction in clinical trials (as selection or stratification criteria)
•   Identify druggable targets 
Patient Outreach and Engagement
•   Develop standardized information about diagnosis and meaning of molecular testing
    using lay language to share across advocacy groups
•   Provide information and training for health care providers
    on educational resources for patients and families 
•   Unify patient registries
Data Sharing and Advanced Molecular Diagnosis 
and Imaging
•   Create research networks with well-defined leadership,
    centralized infrastructure, clearly defined policies (data sharing,
    authorship) and funding  
•   Use untapped sources of data (SEER, GICC, GLIOGENE,
    Nurses’ Health Study, AACR GENIE)
•   Collect hypothesis-generating rather than only hypothesis-driven
    data  
•   Collaborate to obtain large longitudinal sample collection with
    clinical annotation, including tissue, serum and CSF-derived
    biomarkers   
•   Standardize and combine imaging data, including advanced
    techniques (perfusion/diffusion, PET, 2-HG) and correlate with
    molecular data  
Clinical Trial Design
•   Develop alternative endpoints to PFS and OS and composite endpoints: growth
     trajectory, seizure control, cognitive function, instrumental ADLs, symptom burden 
•   Use randomization rather than historical controls
•   Consider Phase 0 designs with tissue acquisition and PD endpoints
•   Obtain contemporary tissue in trials for recurrence
•   Mandate tissue collection for future molecular studies
•   Overcome roadblocks for international collaboration
Figure 4. Workshop recommendations.
  











conducting either basket or umbrella studies in oligo-
dendroglioma with shared molecular features with other 
rare CNS tumors.
Patient Outreach and Engagement
Session Leads: Brittany Cordeiro, Terri 
S. Armstrong, Ph.D., and Mark R. Gilbert, M.D., 
NCI-CONNECT
Patients need more standardized and reliable information 
about diagnosis and treatment for their own consumption 
and for sharing across groups. For example, patients might 
be misleadingly told that they have the “good tumor” 
when being diagnosed with a 1p/19q codeletion and not 
receive the same prognostic information as others with the 
same diagnosis. Along with discussions about prognosis, 
guidance regarding impact of the disease on daily life is 
also critical, including issues with loss of independence (in-
ability to return to previous work, driving restrictions) and 
family planning for patients in their reproductive years. 
Contradictory or inaccurate information can not only in-
fluence treatment decisions but also deter research partic-
ipation. For example, patients need to understand the still 
uncertain clinical implications of the preliminary findings 
regarding hypermutation and how that might or might not 
influence treatment decisions. In addition, standardized 
information and training for providers is a critical need. 
NCI-CONNECT can be a valuable and trusted resource in 
communicating accurate information to the patient and 
provider communities about research, diagnosis, and new 
treatment options. Finally, patient registries are an impor-
tant resource for patients to both provide and receive crit-
ical clinical and research information.
Conclusions, Recommendations and 
Action Plan
An important contribution of NCI-CONNECT is its 
ability to bring experts in rare CNS cancers together 
to share insights, ideas, and plans for collaboration. 
Oligodendroglioma is one of the 12 rare CNS cancers in-
cluded in the initial NCI-CONNECT portfolio. Although 
oligodendrogliomas typically have better prognoses than 
other primary brain tumors, they still have highly vari-
able clinical outcomes, and little is known about the path-
ways involved with progression or the optimal markers for 
stratifying risk. Current therapies are effective in control-
ling tumor growth for prolonged periods of time in many 
instances, but they are usually not curative, and both the 
tumor itself and the treatments are often linked to long-
term sequalae and increased symptom burden with a neg-
ative impact on quality of life.
This report summarizes the discussion and recom-
mendations of the Oligodendroglioma Workshop held on 
November 19, 2018 and provides a call to action to ad-
dress the challenges noted in oligodendroglioma care 
and research. The recommendations of the workshop are 
summarized in Figure 4 and include a multifaceted and 
interrelated approach covering four distinct areas: biology 
and preclinical models, data sharing and advanced molec-
ular diagnosis and imaging, clinical trial design, and pa-
tient outreach and engagement.
The NCI-CONNECT program is well positioned to address 
many of these needs in collaboration with other stakeholders, 
and a list of action items emanated from the workshop and is 
currently being worked on. The Natural History study with its 
longitudinal collection of clinical data along with tumor tissue 
and germline samples is serving as a platform for interaction 
with investigators from other sites to unify patient registries 
and collaborate on tumor tissue analysis (from both newly 
diagnosed and recurrent tumors) as well as germline analysis 
from other large tumor repositories.
Another contribution of the NCI-CONNECT program is a 
clinical trial infrastructure in which only industry support to 
provide the experimental agent/s is necessary. Conducting 
multi-institutional collaborative umbrella or basket trials 
for oligodendrogliomas together with other rare CNS tu-
mors sharing the same molecular features is possible. 
Finally, partnering with advocacy groups and patients is 
critical to NCI-CONNECT, and development of informa-
tional resources for patients and health care providers falls 
within its mission.
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